Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| With a potential BLA submission in 2026, we're well positioned to bring forth the first ever In Vivo CRISPR-based therapy |
| 2023 was an outstanding year for Intellia and its strong momentum has carried into 2024 with our two lead programs either in or approaching Phase 3 clinical development, we are now closer than ever to the first In Vivo CRISPR based therapies reaching the market |
| The physicians are already very excited about our therapy so that first of all they have seen that we have a very consistent and deeper reduction in TPR |
| Offering potentially unmatched clinical profiles would address significant patient unmet need in two large and rapidly growing commercial markets |
| But I think that it's just important to note at this point, that we're making excellent progress and doing everything that we want the technology to do |
| And we're very excited about being in a position to take what we think will be the very first In Vivo CRISPR based approach to approval and go into what we think is a marketplace that we can be extremely successful in |
| So we do feel very confident that the safety database we're bringing will be satisfying what the regulators want |
| We feel very good about the margin |
| But we're convinced that the work that they've done with LNP delivery to the lung, puts us into a really interesting position where we can take the gene writing approach that we've developed and go and address a variety of different genetic lesions that are currently unsatisfied for patients with CF |
| It is this expansive and modular platform coupled with our strong balance sheet that will allow us to achieve the three-year strategic priorities announced earlier this year |
| We're confident in our ability to deliver on these ambitious goals |
| We have a proven track record of success with regulators in advancing CRISPR-based therapies and clinical trials |
| So all things considered, we think we're in a really good position |
| Intellia continues to maintain a strong balance sheet that allows us to execute on our pipeline and platform |
| Of course, this is subject to regulatory feedback, but we think we're in an excellent position |
| And that gives us safety |
| This allows us to address diseases where there is a meaningful opportunity to improve the standard of care |
| This milestone puts Intellia at three for three In Vivo IND clearances within 30 days of submission, a testament to our high standard for drug development |
| With five special regulatory designations granted to 2002, we've taken advantage of the opportunities for additional interactions with the FDA and other agencies to gain early alignment on our Phase 3 plan |
| And we do think a positive HELIOS-B study is a positive for us as well, it would show that TTR reduction is a value to patients with cardiomyopathy, but the hypothesis that really all the experts really believe in |
| And we're excited with what that brings to us to add to the work that we're already doing |
| We have a strong gene editing technology that allows us to target specific mutations, and they bring in validated delivery modalities |
| And finally, we have a world-class team of drug developers who have pioneered some of the most innovative and commercially successful medicines in history |
| We are making great progress and expect many additional sites to ramp up throughout the year |
| And, of course, we're really excited about getting that information, which we think will address not only what we're doing with 3001, but a whole plethora of other sorts of insertion programs that will be associated with that |
| We're really excited about the work that we're embarking on with ReCode |
| Certainly over the last few years, progress has been made in the pharmacopoeia for HAE patients, which is great news |
| So the expression is driven by albumin, which is a really strong promoter |
| But based on everything we've seen thus far, based on our own data, the data that's accumulated by others, we're very confident and satisfied with the trial design that we have |
| So again, we're confident in what we have with the design with a larger study than HELIOS-B at 750 patients |
| Statement |
|---|
| Our collaboration revenue decreased by $15.5 million to negative $1.9 million during the fourth quarter of 2023, compared to $13.6 million during the fourth quarter of 2022 |
| We have seen cell lines where the expression of the mutant form that will lead us to a concern with regards to exacerbation of aggregation after 3001 treatment |
| The fundamental problem, the challenge for patients that we hear from doctors and from patients themselves is to make attacks go away, make them be in a position where they never have to worry about an attack and don't have to carry on-demand therapy |
| So as new forms of on-demand therapy come out that fundamentally we don't think addresses what patients are looking for, and from a prophylactic point of view, as long as those drugs need to be readministered, that is going to be a continuing burden for those patients |
| We have seen in our study patients withdrawing from Lenzilumab [ph] as well as other prophylactic therapies |
| And even more advanced augmentation therapies haven't attempted to show this improvement |
| The other measures like six-minute walk have had inconsistent results in recent studies, as you've seen, and we don't think is a really important part of what's happening for patients, especially because they may have other things other than their heart disease that's really affecting their six-minute walk, as these are older patients |
| If you imagine some of the studies we've seen, some patients who are -- can be quite healthy despite having some early heart failure and those patients have very few events and therefore contribute very little to the findings in the study |
| This decrease was mainly driven by a $10.3 million one-time revenue recognition adjustment related to Regeneron extending the technology collaboration to April 2026 |
Please consider a small donation if you think this website provides you with relevant information